Tempus will use bioinformatics and machine learning to analyze molecular, phenotypic, therapeutic and outcomes data for hundreds of breast cancer patients. Tempus and U-M researchers will analyze this data alongside the university’s patient-derived biological models, which alert providers to the drugs that will prove most effective for individual patients.
This agreement marks U-M’s second collaboration with Tempus. The organizations partnered to bring U-M’s DNA-sequencing panel, MI-ONCOSEQ, to cancer patients across the country in October.
More articles on health IT:
House allocates $65M to modernize VA EHRs
Philips opens 1st innovation center in Russia
69% of organizations don’t routinely test security controls, survey finds
